Similar articles for PMID: 30013379

Year	Number of Results
1991	1
1995	2
1998	2
2000	1
2002	1
2003	1
2004	2
2006	3
2007	2
2009	10
2010	10
2011	7
2012	10
2013	12
2014	4
2015	3
2016	6
2017	10
2018	10
2019	3
2020	3
2021	5
2022	1
2023	1
2024	0

1

Comparison of botulinum neurotoxin type A formulations in Asia.

Frevert J, Ahn KY, Park MY, Sunga O. Frevert J, et al. Clin Cosmet Investig Dermatol. 2018 Jul 5;11:327-331. doi: 10.2147/CCID.S160723. eCollection 2018. Clin Cosmet Investig Dermatol. 2018. PMID: 30013379 Free PMC article.

2

Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®.

Frevert J. Frevert J. Drugs R D. 2010;10(2):67-73. doi: 10.2165/11584780-000000000-00000. Drugs R D. 2010. PMID: 20698714 Free PMC article.

3

Neurotoxin Impurities: A Review of Threats to Efficacy.

Park JY, Sunga O, Wanitphakdeedecha R, Frevert J. Park JY, et al. Plast Reconstr Surg Glob Open. 2020 Jan 24;8(1):e2627. doi: 10.1097/GOX.0000000000002627. eCollection 2020 Jan. Plast Reconstr Surg Glob Open. 2020. PMID: 32095419 Free PMC article.

4

AbobotulinumtoxinA (Dysport^®), OnabotulinumtoxinA (Botox^®), and IncobotulinumtoxinA (Xeomin^®) Neurotoxin Content and Potential Implications for Duration of Response in Patients.

Field M, Splevins A, Picaut P, van der Schans M, Langenberg J, Noort D, Snyder D, Foster K. Field M, et al. Toxins (Basel). 2018 Dec 13;10(12):535. doi: 10.3390/toxins10120535. Toxins (Basel). 2018. PMID: 30551641 Free PMC article.

5

Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasm.

Park J, Lee MS, Harrison AR. Park J, et al. Clin Ophthalmol. 2011;5:725-32. doi: 10.2147/OPTH.S13978. Epub 2011 Jun 1. Clin Ophthalmol. 2011. PMID: 21691580 Free PMC article.

6

Potency evaluation of a formulated drug product containing 150-kd botulinum neurotoxin type A.

Hunt T, Clarke K. Hunt T, et al. Clin Neuropharmacol. 2009 Jan-Feb;32(1):28-31. doi: 10.1097/WNF.0B013E3181692735. Clin Neuropharmacol. 2009. PMID: 18978494

7

The science and manufacturing behind botulinum neurotoxin type A-ABO in clinical use.

Wortzman MS, Pickett A. Wortzman MS, et al. Aesthet Surg J. 2009 Nov;29(6 Suppl):S34-42. doi: 10.1016/j.asj.2009.09.014. Aesthet Surg J. 2009. PMID: 19945003 Review.

8

Xeomin^®, a Commercial Formulation of Botulinum Neurotoxin Type A, Promotes Regeneration in a Preclinical Model of Spinal Cord Injury.

Mastrorilli V, De Angelis F, Vacca V, Pavone F, Luvisetto S, Marinelli S. Mastrorilli V, et al. Toxins (Basel). 2023 Mar 28;15(4):248. doi: 10.3390/toxins15040248. Toxins (Basel). 2023. PMID: 37104185 Free PMC article.

9

Studies on the dissociation of botulinum neurotoxin type A complexes.

Eisele KH, Fink K, Vey M, Taylor HV. Eisele KH, et al. Toxicon. 2011 Mar 15;57(4):555-65. doi: 10.1016/j.toxicon.2010.12.019. Epub 2010 Dec 30. Toxicon. 2011. PMID: 21195107

10

Comparative immunochemical characteristics of botulinum neurotoxin type A and its associated proteins.

Bryant AM, Cai S, Singh BR. Bryant AM, et al. Toxicon. 2013 Sep;72:126-32. doi: 10.1016/j.toxicon.2013.06.011. Epub 2013 Jun 28. Toxicon. 2013. PMID: 23811077 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year